| HOME >> BIOLOGY >> TECHNOLOGY |
SAN FRANCISCO, May 26 /PRNewswire/ -- Vaxart, Inc., a biotechnology company focused on the development of oral vaccines, announced today that the company has created a candidate vaccine for H1N1 influenza (swine flu). On Saturday, May 23, Vaxart began testing for immune responses in animals, just 25 days after initiating the project. The company will compare performance of the research-grade H1N1 vaccine to its successful avian flu vaccine as a first step towards potential human clinical testing.
The company has also begun preparing source material suitable for production of human H1N1 vaccine; an initial batch could be produced by August. However, human testing may not begin until fall or later, due to the need for safety testing in animals.
"Our oral vaccine could provide an important tool for swine flu pandemic preparation, because of the speed with which it could be delivered to groups such as first-line medical personnel," said Sean Tucker, Ph.D., Vaxart vice president of research.
Currently, pandemic flu vaccines are prepared by a slow and inefficient process that requires about six months before the first large amounts of vaccine are available. This process depends on creating an engineered variant of the circulating pandemic influenza strain and growing it in eggs. An advantage of Vaxart's approach is that it does not require culturing the flu virus in eggs; company scientists make a new vaccine by inserting a small piece of DNA matching the pandemic strain into Vaxart's pre-constructed vector. Vaxart's vector grows quickly and reproducibly in cell culture using a standard process.
Vaxart vaccines are novel in several ways, including the fact that they can be taken orally (i.e., by swallowing a capsule). In addition, the product is stable enough to be distributed without refrigeration. In an emergency, an approved Vaxart vaccine could be supplied by mail, rather than risking the sprea
'/>"/>
| SOURCE Vaxart, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
2. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
3. Genzyme Begins Major Expansion of Boston Manufacturing Facility
4. Medical Services Begins Working With United States Companies for Distribution of Its Products
5. Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base
6. Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health
7. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
8. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
9. Ohio Task Force Begins Mission of Creating a New 21st Century Industry
10. Thomson Scientific Begins Expansion of Web of Science
11. Nikon Instruments Begins Direct Sales and Technical Support in Southern California and Rocky Mountain Territories
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |